Want to see IMMP full AI Analyst Report?
Top Page
Immutep
(NASDAQ:IMMP)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.36
▼(-82.60% Downside)
Action:Reiterated
Date:06/02/26
The score is primarily weighed down by weak financial performance (ongoing losses and negative operating/free cash flow). Technicals also remain unfavorable with the stock trading below major moving averages and negative MACD, while valuation metrics provide limited support due to a negative P/E and no dividend yield.
Positive Factors
LAG‑3 platform leadership
Immutep’s concentrated expertise in LAG‑3 biology with multiple distinct programs across oncology and autoimmune indications creates a durable platform advantage. A focused scientific moat increases probability of repeatable opt‑ins by partners and multiple value-creation pathways beyond any single asset.
Negative Factors
Persistent negative cash flow
Chronic operating and free cash flow deficits are a durable constraint for a clinical‑stage biotech, forcing reliance on partners or capital markets. Ongoing cash burn can limit trial scope, delay development timelines and dilute existing shareholders if recurring financing is required to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
LAG‑3 platform leadership
Immutep’s concentrated expertise in LAG‑3 biology with multiple distinct programs across oncology and autoimmune indications creates a durable platform advantage. A focused scientific moat increases probability of repeatable opt‑ins by partners and multiple value-creation pathways beyond any single asset.
Read all positive factors
Immutep (IMMP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$48.61M
Dividend YieldN/A
Average Volume (3M)863.74K
Price to Earnings (P/E)―
Beta (1Y)2.20
Revenue GrowthN/A
EPS Growth-69.60%
CountryUS
Employees53
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.57
Shares Outstanding147,372,130
10 Day Avg. Volume390,585
30 Day Avg. Volume863,739
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit-0.06
Enterprise Value/Ebitda-0.06
Forecast
1Y Price Target
$1.50Price Target Upside-26.47% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$4.09M
Immutep Business Overview & Revenue Model
Company Description
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a solu...
How the Company Makes Money
Immutep’s business model is typical of a clinical-stage biotech: it primarily seeks to create value and generate cash through partnering its drug candidates rather than through product sales (as it does not have widely marketed, commercial product...
Immutep Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.92M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -74.78M | -56.37M | -37.70M | 1.44M | -1.89M | -13.37M |
| EBITDA | -81.38M | -62.88M | -44.54M | -39.57M | -31.87M | -17.77M |
| Net Income | -83.92M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 147.20M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 99.13M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 1.21M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 48.30M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 98.90M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -61.75M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -61.63M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | 58.95M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -208.44K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Technical Analysis
Negative
2.04
Price Trends
0.45
Negative
1.05
Negative
1.64
Negative
Market Momentum
-0.02
Negative
43.75
Neutral
79.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Negative. The current price of 2.04 is above the 20-day moving average (MA) of 0.38, above the 50-day MA of 0.45, and above the 200-day MA of 1.64, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 43.75 is Neutral, neither overbought nor oversold. The STOCH value of 79.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMMP.
Immutep Risk Analysis
Immutep disclosed 52 risk factors in its most recent earnings report. Immutep reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immutep Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $478.96M | -2.50 | -121.71% | ― | ― | ― | |
55 Neutral | $276.77M | -1.66 | 194.13% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $202.10M | -4.21 | -80.61% | ― | 43.21% | -15.55% | |
45 Neutral | $270.91M | -0.75 | -85.71% | ― | -52.31% | 49.06% | |
40 Underperform | $48.61M | -0.87 | -69.20% | ― | ― | -69.60% |
* Healthcare Sector Average
IMMP
Immutep
0.41
-1.23
-75.18%
CLLS
Cellectis SA
2.94
1.42
93.42%
RNAC
Cartesian Therapeutics
9.64
-0.75
-7.22%
SLN
Silence Therapeutics
10.79
4.99
86.03%
LYEL
Lyell Immunopharma
12.75
3.91
44.23%
Immutep Corporate Events
Immutep Reports Positive Phase I Data for First-in-Class LAG-3 Agonist IMP761
Jun 5, 2026
On June 4, 2026, Immutep announced positive interim results from a first-in-human Phase I trial of its lead autoimmune candidate IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers. The randomized, placebo-controlled, double-bli...
Immutep Halts Key Lung Cancer Phase III Trial but Maintains Strong Cash Position and Pipeline Progress
May 1, 2026
In March 2026, Immutep discontinued its Phase III TACTI-004 trial in first-line non-small cell lung cancer after an interim futility analysis showed patients on eftilagimod alfa with KEYTRUDA and chemotherapy underperformed the placebo combination...
Immutep Faces Nasdaq Bid-Price Warning but Retains Dual Listings
May 1, 2026
On April 30, 2026, Immutep Limited disclosed that it received a notice from Nasdaq stating its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of US$1.00, after trading below that threshold for 30 conse...
Immutep Wins FDA Orphan Drug Status for Eftilagimod Alfa in Soft Tissue Sarcoma
Apr 16, 2026
On April 15, 2026, Immutep announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to its lead candidate eftilagimod alfa for treating soft tissue sarcoma, a rare cancer with high unmet need. The status, which can prov...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.